Tango Therapeutics, Inc. (TNGX) financials: revenue, earnings and cash flow
Fiscal 2020–2025 · from SEC filings · data as of November 16, 2026
Summary
Tango Therapeutics’s revenue went from $8M in fiscal 2020 to $62M in fiscal 2025, growth of about 52.1% a year.
Net income in fiscal 2025 was -$102M, a net margin of -162.9%; the best year in this period was 2020 with -$52M.
Free cash flow was -$140M in fiscal 2025 and positive in 1 of the 6 years shown.
The diluted share count rose 264% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $62M | $42M | $37M | $25M | $37M | $8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$111M | -$146M | -$114M | -$111M | -$58M | -$52M |
| Net income | -$102M | -$130M | -$102M | -$108M | -$58M | -$52M |
| EPS (diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 | $-1.63 |
| R&D | $132M | $144M | $115M | $106M | $78M | $50M |
| Revenue growth | +48.3% | +15.2% | +46.9% | −32.9% | +383.8% | — |
Cash flow
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$139M | -$132M | -$118M | -$109M | -$60M | $70M |
| Capital spending | -$1M | -$754000 | -$2M | -$8M | -$2M | -$1M |
| Free cash flow | -$140M | -$132M | -$120M | -$117M | -$61M | $69M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — |
| Stock-based pay | $26M | $29M | $19M | $14M | $8M | $2M |
Balance sheet
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Cash | $343M | $258M | $337M | $366M | $485M | $190M |
| Debt | $34M | $36M | $36M | $41M | $2M | $8M |
| Equity | $346M | $200M | $253M | $249M | $345M | $39M |
| Total assets | $399M | $316M | $403M | $436M | $500M | $207M |
| Shares (diluted) | 116M | 109M | 95M | 88M | 62M | 32M |
Margins and returns
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — |
| Operating margin | -178.4% | -346.1% | -312.6% | -446.8% | -157.1% | -681.8% |
| Net margin | -162.8% | -309.7% | -278.5% | -435.1% | -157.2% | -678.8% |
| FCF margin | -224.3% | -314.4% | -327.2% | -469.7% | -165.7% | 900.8% |
| ROIC | -23.2% | -48.7% | -31.1% | -30.2% | -13.3% | -112.3% |
| ROE | -29.3% | -65.3% | -40.2% | -43.4% | -16.9% | -134.6% |
Frequently asked questions
What is Tango Therapeutics’s annual revenue?
$62M in fiscal 2025.
How much profit does Tango Therapeutics make?
Net income was -$102M in fiscal 2025 (net margin -162.9%).
Is Tango Therapeutics’s revenue growing?
Yes: revenue rose 48.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.